Nkarta (NKTX) Interest & Investment Income (2019 - 2026)
Nkarta's quarterly Interest & Investment Income came in at $2.8 million in Q1 2026, down 35.15% year-on-year from $4.4 million in Q1 2025, and down 13.9% quarter-over-quarter from $3.3 million in Q4 2025.
Nkarta has reported Interest & Investment Income for 8 years, with the latest figure at $2.8 million in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income fell 35.15% year-over-year to $2.8 million; the trailing twelve-month figure through Mar 2026 stood at $14.0 million (down 31.75% YoY), and the FY2025 full-year result was $15.5 million, down 19.79% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $2.8 million, down from $3.3 million in the prior quarter.
- The five-year high for Interest & Investment Income was $5.7 million in Q2 2024, with the low at $112000.0 in Q1 2022.
- Average Interest & Investment Income over 5 years is $3.4 million, with a median of $3.5 million recorded in 2023.
- Year-over-year, Interest & Investment Income jumped 3753.33% in 2022 and tumbled 35.15% in 2026.
- Tracing NKTX's Interest & Investment Income over 5 years: stood at $2.9 million in 2022, then gained by 19.58% to $3.5 million in 2023, then jumped by 41.61% to $4.9 million in 2024, then plunged by 32.65% to $3.3 million in 2025, then dropped by 13.9% to $2.8 million in 2026.
- The last three Interest & Investment Income figures came in at $2.8 million (Q1 2026), $3.3 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - | 2.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.84 Mn |
| Dec 31, 2025 | 3.30 Mn |
| Sep 30, 2025 | 3.85 Mn |
| Jun 30, 2025 | 3.97 Mn |
| Mar 31, 2025 | 4.38 Mn |
| Dec 31, 2024 | 4.89 Mn |
| Sep 30, 2024 | 5.45 Mn |
| Jun 30, 2024 | 5.72 Mn |
| Mar 31, 2024 | 3.25 Mn |
| Dec 31, 2023 | 3.46 Mn |
| Sep 30, 2023 | 3.62 Mn |
| Jun 30, 2023 | 3.57 Mn |
| Mar 31, 2023 | 3.47 Mn |
| Dec 31, 2022 | 2.89 Mn |
| Sep 30, 2022 | 1.90 Mn |
| Jun 30, 2022 | 686,000.00 |
| Mar 31, 2022 | 112,000.00 |
| Dec 31, 2021 | 75,000.00 |
| Sep 30, 2021 | 81,000.00 |
| Jun 30, 2021 | 104,000.00 |
| Mar 31, 2021 | 110,000.00 |
| Dec 31, 2020 | -45,000.00 |
| Sep 30, 2020 | 206,000.00 |
| Jun 30, 2020 | 27,000.00 |
| Mar 31, 2020 | 124,000.00 |
| Dec 31, 2019 | 244,000.00 |
| Sep 30, 2019 | 246.00 |
| Jun 30, 2019 | 21,855.00 |